President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Moderna ( (MRNA) ) just unveiled an update.

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderna's chief technical operations officer explains why now is the right time to take full control of the company's ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Moderna closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds (Ares) to increase flexibility. The non-dilutive debt financing consists of three ...